Zentalis Pharmaceuticals (ZNTL) began trading on the Nasdaq on Fri 3 Apr 2020

Zentalis Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers in the United States.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 
• Founded in 2014 
• HQ in New York, New York
• http://www.zentalis.com

Zentalis CEO Anthony Sun

Zentalis inked a clinical development deal with Pfizer in May 2018 to test the drug alongside the Big Pharma’s CDK4/6 inhibitor Ibrance (palbociclib). It expects to report data from a phase 1/2 study of ZN-c5 in combination with Ibrance, as well as a single agent, in 2020.

Its clinical pipeline also includes ZN-c3, which targets the WEE1 kinase to treat solid tumors, and an EGFR med for lung cancer. Zentalis plans to move its fourth program, a drug targeting BCL-2 in blood cancers, into the clinic by the middle of 2020, Sun told us last year. The preclinical pipeline comprises a pair of programs in blood cancers and solid tumors.